Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effectiveness and safety of an antiretroviral
therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as
first-line therapy in treatment-naïve participants.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)